Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Exp Physiol. 2017 Dec 7;103(2):236–249. doi: 10.1113/EP086604

Fig 4.

Fig 4

A. In-line mean arterial pressure (MAP) and B. heart rate (HR) measurement. Values are expressed as mean ± SD. *P < 0.05, and #P < 0.05 for the control vs glucose, and glucose vs G+captopril, G+tempol treated group, respectively (one-way ANOVA followed by Tukey-Kramer posttests). B. Heart rate: There was no significant difference in HR between all groups.